keyword
https://read.qxmd.com/read/38508664/the-nitric-oxide-soluble-guanylate-cyclase-cgmp-pathway-in-pulmonary-hypertension-from-pde5-to-soluble-guanylate-cyclase
#1
REVIEW
Raymond L Benza, Ekkehard Grünig, Peter Sandner, Johannes-Peter Stasch, Gérald Simonneau
The nitric oxide (NO)-soluble guanylate cyclase (sGC)-cyclic guanosine monophosphate (cGMP) pathway plays a key role in the pathogenesis of pulmonary hypertension (PH). Targeted treatments include phosphodiesterase type 5 inhibitors (PDE5i) and sGC stimulators. The sGC stimulator riociguat is approved for the treatment of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). sGC stimulators have a dual mechanism of action, enhancing the sGC response to endogenous NO and directly stimulating sGC, independent of NO...
January 31, 2024: European Respiratory Review: An Official Journal of the European Respiratory Society
https://read.qxmd.com/read/38490689/association-of-sildenafil-use-with-age-related-macular-degeneration-a-retrospective-cohort-study
#2
JOURNAL ARTICLE
Ji Eun Diana Han, Anuradhaa Subramanian, Wen Hwa Lee, Jesse Coker, Alastair K Denniston, Krishnarajah Nirantharakumar, Nicola Jaime Adderley
OBJECTIVE: Despite significant advances in clinical care and understanding of the underlying pathophysiology, age-related macular degeneration (AMD)-a major cause of global blindness-lacks effective treatment to prevent the irreversible degeneration of photoreceptors leading to central vision loss. Limited studies suggest phosphodiesterase type 5 (PDE5) inhibitors, such as sildenafil, may prevent AMD by increasing retinal blood flow. This study explores the potential association between sildenafil use and AMD risk in men with erectile dysfunction using UK data...
March 15, 2024: BMJ Open Ophthalmology
https://read.qxmd.com/read/38487305/safety-tolerability-and-pharmacokinetics-of-aildenafil-citrate-tablets-a-novel-oral-pde5-inhibitor-in-healthy-chinese-volunteers-after-multiple-dose-administration
#3
JOURNAL ARTICLE
Ran Xie, Bo Jia, Lu Cheng, Nan Zhao, Xu He, Xia Wang, Xia Zhao, Yimin Cui
BACKGROUND: Aildenafil citrate is a potent and selective inhibitor of cyclic guanosine monophosphate-specific phosphodiesterase type 5, developed for the treatment of erectile dysfunction (ED). AIM: This study aimed to assess the pharmacokinetics, safety, and tolerability of aildenafil citrate tablets after multiple doses in healthy Chinese males. METHODS: Twenty participants were divided into 2 groups, 10 participants each. Participants were administered multiple doses of aildenafil citrate tablets at 30 and 60 mg...
February 2024: Sexual Medicine
https://read.qxmd.com/read/38458412/sildenafil-alone-and-in-combination-with-imipramine-or-escitalopram-display-antidepressant-like-effects-in-an-adrenocorticotropic-hormone-induced-acth-rodent-model-of-treatment-resistant-depression
#4
JOURNAL ARTICLE
Juandré Lambertus Bernardus Saayman, Brian Herbert Harvey, Gregers Wegener, Christiaan Beyers Brink
BACKGROUND: Major depressive disorder (MDD) represents a challenge with high prevalence and limited effectiveness of existing treatments, particularly in cases of treatment-resistant depression (TRD). Innovative strategies and alternative drug targets are therefore necessary. Sildenafil, a selective phosphodiesterase type 5 (PDE5) inhibitor, is known to exert neuroplastic, anti-inflammatory, and antioxidant properties, and is a promising antidepressant drug candidate. AIM: To investigate whether sildenafil monotherapy or in combination with a known antidepressant, can elicit antidepressant-like effects in an adrenocorticotropic hormone (ACTH)-induced rodent model of TRD...
March 6, 2024: European Journal of Pharmacology
https://read.qxmd.com/read/38454969/penile-rehabilitation-effectiveness-after-prostate-cancer-treatment-a-systematic-review-of-randomized-controlled-trials
#5
JOURNAL ARTICLE
Roshan Prasad, Mayur Wanjari, Yeshwant R Lamture, Sampada Late, Ranjana Sharma
Prostate cancer treatment can significantly impact erectile function, and penile rehabilitation has been proposed to improve the impacts. However, the effectiveness of penile rehabilitations after treatment of prostate cancer is scarce. The aim of this systematic review was to evaluate the effectiveness of different interventions of penile rehabilitation program after prostate cancer treatment. We conducted a comprehensive search of electronic databases, PubMed and Google Scholar, to identify randomized controlled trials that evaluated interventions for penile rehabilitation after prostate cancer treatment...
August 2023: Narra J
https://read.qxmd.com/read/38448685/medical-advancements-in-benign-prostatic-hyperplasia-treatments
#6
REVIEW
Vishnuvardhan Ganesan, Deepak Agarwal
PURPOSE OF REVIEW: This review aims to identify and summarize the current literature on the most recent therapeutic agents and combination strategies for the medical management of lower urinary tract symptoms resulting from benign prostatic hyperplasia. RECENT FINDINGS: The latest advancements in BPH therapy have been in combination strategies. Alpha blockers continue to be the mainstay of treatment, but research is exploring the synergistic benefits of combining them with 5-alpha reductase inhibitors (5-ARIs), phosphodiesterase-5 (PDE5) inhibitors, and beta-3 agonists...
March 7, 2024: Current Urology Reports
https://read.qxmd.com/read/38430555/bifunctional-sildenafil-diazeniumdiolates-acting-as-phosphodiesterase-5-inhibitors-and-nitric-oxide-donors-%C3%AC-towards-wound-healing
#7
JOURNAL ARTICLE
Josep Mas-Roselló, Hermann Tenor, Timea Szabo, Reto Naef, Simon Sieber, Karl Gademann
Inefficient wound healing poses a global health challenge with a lack of efficient treatments. Wound healing issues often correlate with low endogenous nitric oxide (NO) levels. While exogenous delivery with NO-releasing compounds represents a promising therapeutic strategy, controlling the release of the highly reactive NO remains challenging. Phosphodiesterase 5 (PDE5) inhibitors, like sildenafil, have also been shown to promote wound healing. This study explores hybrid compounds, combining NO-releasing diazeniumdiolates with a sildenafil-derived PDE5 inhibitor...
March 2, 2024: Chembiochem: a European Journal of Chemical Biology
https://read.qxmd.com/read/38427489/sildenafil-as-a-candidate-drug-for-alzheimer-s-disease-real-world-patient-data-observation-and-mechanistic-observations-from-patient-induced-pluripotent-stem-cell-derived-neurons
#8
JOURNAL ARTICLE
Dhruv Gohel, Pengyue Zhang, Amit Kumar Gupta, Yichen Li, Chien-Wei Chiang, Lang Li, Yuan Hou, Andrew A Pieper, Jeffrey Cummings, Feixiong Cheng
BACKGROUND: Alzheimer's disease (AD) is a chronic neurodegenerative disease needing effective therapeutics urgently. Sildenafil, one of the approved phosphodiesterase-5 inhibitors, has been implicated as having potential effect in AD. OBJECTIVE: To investigate the potential therapeutic benefit of sildenafil on AD. METHODS: We performed real-world patient data analysis using the MarketScan® Medicare Supplemental and the Clinformatics® databases...
March 1, 2024: Journal of Alzheimer's Disease: JAD
https://read.qxmd.com/read/38423706/avanafil-a-comprehensive-drug-profile
#9
JOURNAL ARTICLE
Abdulrahman A Al-Majed, Amer AlKhairallah, Mohamed W Attwa, Hamad M Alkahtani, Adel S El-Azab, Alaa A-M Abdel-Aziz, Ayman Alkhider, Sawsan Bushra Hassan, Ahmed H Bakheit
Avanafil is an oral medication used to treat erectile dysfunction (ED). As a phosphodiesterase type 5 (PDE5) inhibitor, it functions by inhibiting the PDE5 enzyme, which ultimately results in increased levels of cyclic guanosine monophosphate (cGMP) and improved blood flow to the penis. Approved by the FDA in 2012, avanafil is recognised for its rapid onset of action, short half-life, and favourable side-effects profile. While it has been explored for other potential therapeutic applications, its current approved use is limited to ED and should be used as prescribed by a medical professional...
2024: Profiles of Drug Substances, Excipients, and related Methodology
https://read.qxmd.com/read/38418867/hard-flaccid-syndrome-symptoms-comorbidities-and-self-reported-efficacy-and-satisfaction-of-treatments-a-cross-sectional-survey
#10
JOURNAL ARTICLE
Jenny Niedenfuehr, David M Stevens
Hard flaccid syndrome (HFS) is a poorly understood condition with no formal consensus on its definition. We aimed to advance the understanding of HFS by evaluating symptom prevalence, cause of symptom onset, comorbidities, and self-reported efficacy and satisfaction with current treatments. An online, open, 42-question survey on Qualtrics with purposive and convenience sampling methods was conducted between May 9 and June 9, 2023 on participants self-identifying as having HFS. Participants were recruited through social media platforms...
February 28, 2024: International Journal of Impotence Research
https://read.qxmd.com/read/38368658/design-synthesis-and-biological-evaluation-of-some-new-2-phenyl-3-6-pyridazinedione-derivatives-as-pde-5-inhibitors
#11
JOURNAL ARTICLE
Zeinab S Abd-Rabo, Riham F George, Dalia K Zaafar, Aya Y Gawish, Aya M Serry
Various 2-phenyl-3,6-pyridazinedione derivatives 4a-j, 5a-c, 6a,b, 7a-c, 8, 9, 10a-d, and 11a-d, were effectivelysynthesized, and tested for their potential inhibition of phosphodiesterase enzyme at 10 µM. Then fourteen compounds exhibiting the highest inhibition 4b, 4d, 4e, 4g, 4h, 4i, 5a, 6a,b, 7c, 10a,b, 11a, and 11d were selected for screening their PDE-5 inhibition, where compounds 4b,g,h, and 11a revealed promising PDE-5 inhibition having IC50 values = 25, 53, 22, and 42 nM, respectively in comparison with Sildenafil (IC50  = 16 nM)...
February 16, 2024: Bioorganic Chemistry
https://read.qxmd.com/read/38350962/cone-photoreceptor-phosphodiesterase-pde6h-inhibition-regulates-cancer-cell-growth-and-metabolism-replicating-the-dark-retina-response
#12
JOURNAL ARTICLE
Ceren Yalaz, Esther Bridges, Nasullah K Alham, Christos E Zois, Jianzhou Chen, Karim Bensaad, Ana Miar, Elisabete Pires, Ruth J Muschel, James S O McCullagh, Adrian L Harris
BACKGROUND: PDE6H encodes PDE6γ', the inhibitory subunit of the cGMP-specific phosphodiesterase 6 in cone photoreceptors. Inhibition of PDE6, which has been widely studied for its role in light transduction, increases cGMP levels. The purpose of this study is to characterise the role of PDE6H in cancer cell growth. METHODS: From an siRNA screen for 487 genes involved in metabolism, PDE6H was identified as a controller of cell cycle progression in HCT116 cells...
February 13, 2024: Cancer & Metabolism
https://read.qxmd.com/read/38327712/a-real-world-pilot-study-assessing-treatment-satisfaction-with-avanafil-in-patients-with-erectile-dysfunction
#13
JOURNAL ARTICLE
Ping-Ju Tsai, Shih-Ya Hung, Tsung-Hsi Lee, Bang-Ping Jiann
BACKGROUND: Avanafil is a second-generation phosphodiesterase type 5 (PDE5) inhibitor, and offers a rapid onset of action (15 minutes). Its real-world data, including treatment satisfaction, are still lacking. AIM: The study sought to investigate the treatment outcomes of avanafil and the factors impacting treatment satisfaction in a real-world setting. METHODS: Between November 2021 and February 2023, erectile dysfunction (ED) patients prescribed avanafil were consecutively enrolled in this phase 4, open-label, cross-sectional, observational study...
February 2024: Sexual Medicine
https://read.qxmd.com/read/38297421/-phytotherapy-and-natural-agents-in-symptomatic-benign-prostatic-hyperplasia-bph
#14
JOURNAL ARTICLE
Menachem Laufer, Shir Shoenfeld
Benign prostatic hyperplasia (BPH) is a very common condition among men over 50 years of age. Some patients require immediate surgical intervention for urinary retention. However, most men have a variety of symptoms that may require treatment. Medical therapy for BPH has been well known for many years including alpha-adrenergic receptor blockers and 5-alpha reductase inhibitors. In recent years, men also receive anti-cholinergic agents, PDE5 inhibitors and other medical interventions. However, many men pursue alternative treatments and herbal medicines for BPH...
January 2024: Harefuah
https://read.qxmd.com/read/38288222/pharmacological-approaches-in-managing-symptomatic-relief-of-benign-prostatic-hyperplasia-a-comprehensive-review
#15
REVIEW
Collyn O'Quin, Kathryn L White, John R Campbell, Sarah H Myers, Shilpadevi Patil, Debbie Chandler, Shahab Ahmadzadeh, Giustino Varrassi, Sahar Shekoohi, Alan D Kaye
Benign Prostatic Hyperplasia (BPH) is a prevalent condition that affects aging men, leading to the development of lower urinary tract symptoms (LUTS) and potentially severe complications such as complete obstruction. The management of BPH typically involves the use of medications from different classes, including alpha-1 antagonists, 5-alpha reductase inhibitors, and anticholinergics. Combination therapy utilizing drugs from different classes can also effectively manage the BPH-LUTS complex. Recent research has revealed that phosphodiesterase 5 (PDE5) inhibitors, including Tadalafil and Sildenafil, are highly effective in treating LUTS associated with BPH...
December 2023: Curēus
https://read.qxmd.com/read/38270120/polypharmacological-potential-of-phosphodiesterase-5-inhibitors-for-the-treatment-of-neurocognitive-disorders
#16
JOURNAL ARTICLE
Ashish Kumar, Fred Kim, Dong-Keun Song, Jai Jun Choung
The prevalence of neurocognitive disorders (NCD) increases every year as the population continues to age, leading to significant global health concerns. Overcoming this challenge requires identifying biomarkers, risk factors, and effective therapeutic interventions that might provide meaningful clinical benefits. For Alzheimer's disease (AD), one of the most studied NCD, approved drugs include acetylcholinesterase inhibitors (rivastigmine, donepezil, and galantamine), an NMDA receptor antagonist (memantine), and anti-amyloid monoclonal antibodies (aducanumab and lecanemab)...
December 14, 2023: Aging and Disease
https://read.qxmd.com/read/38262744/nitric-oxide-resistance-in-priapism-associated-with-sickle-cell-disease-mechanisms-therapeutic-challenges-and-future-directions
#17
JOURNAL ARTICLE
Dalila Andrade Pereira, Fabiano Beraldi Calmasini, Fernando Ferreira Costa, Arthur L Burnett, Fábio Henrique Silva
Patients with sickle cell disease (SCD) display priapism, a prolonged penile erection in the absence of sexual arousal. The current pharmacological treatments for SCD-associated priapism are limited and focused on acute interventions rather than prevention. Thus, there is an urgent need for new drug targets and preventive pharmacological therapies for this condition. This review focuses on the molecular mechanisms linked to the dysfunction of the NO-cyclic guanosine monophosphate (cGMP)-phosphodiesterase type 5 (PDE5) pathway implicated in SCD-associated priapism...
January 23, 2024: Journal of Pharmacology and Experimental Therapeutics
https://read.qxmd.com/read/38262296/application-of-terahertz-time-domain-spectroscopy-and-chemometrics-based-whale-optimization-algorithm-in-pde5-inhibitor-detection
#18
JOURNAL ARTICLE
Aolin Zhang, Ge Qin, Jifen Wang, Na Li, Shihao Wu
Combating the illicit use of PDE5 inhibitor drugs is a focal point in forensic science research. In order to achieve rapid identification of such drugs, this study applies terahertz time-domain spectroscopy combined with chemometrics to establish a fast and accurate detection method for PDE5 inhibitors. The optimal detection method is determined by comparing the spectral performance of three optical parameters, namely absorption coefficient, refractive index, and dielectric constant. Linear discriminant models based on different spectral parameters, whale optimization algorithm optimized extreme learning machine models, and whale optimization algorithm optimized random forest models are established...
January 19, 2024: Spectrochimica Acta. Part A, Molecular and Biomolecular Spectroscopy
https://read.qxmd.com/read/38236522/hesperetin-relaxes-depolarizing-contraction-in-human-umbilical-vein-by-inhibiting-l-type-ca-2-channel
#19
JOURNAL ARTICLE
Kritsana Tipcome, Wattana B Watanapa, Katesirin Ruamyod
OBJECTIVE: To study hesperetin-induced vasorelaxation after depolarizing contraction in human umbilical veins (HUVs) to elucidate the role of L-type Ca2+ channel (LTCC) and related signaling pathway. METHODS: Isometric tension recording was performed in HUV rings pre-contracted with K+ . Hesperetin relaxing mechanism was investigated using a LTCC opener (BayK8644) and blockers of cyclic nucleotides and phosphodiesterases (PDEs). Whole-cell patch-clamping in A7r5 cells, a rat vascular smooth muscle cell line, was performed to study the effect of hesperetin on LTCC current...
January 18, 2024: Chinese Journal of Integrative Medicine
https://read.qxmd.com/read/38232236/insights-on-protective-effect-of-platelet-rich-plasma-and-tadalafil-on-testicular-ischemia-reperfusion-injury-in-rats-exposed-to-testicular-torsion-detorsion
#20
JOURNAL ARTICLE
Dalia M Abdel Ghaffar, Zienab Helmy Eldken, Mohammed S Sultan, Rania M Khalil, Noha Hamma Sakr, Hanan Eissa, Sally M Safwat
BACKGROUND/AIMS: Ischemic reperfusion (I-R) injury is greatly influenced by the testicular torsion/detorsion process (TDP). In this instance, the anti-inflammatory properties of plateletrich plasma (PRP) combined with tadalafil (Td) significantly promote tissue healing in the I-R injury model. METHODS: Five groups of rats were created: the control group, the I-R group not receiving any therapy, the I-R group receiving a single dosage of Td (0.25 mg/kg, I.P.), the I-R group receiving a single dose of PRP (80 l, intratesticular), and the I-R group receiving both Td and PRP...
January 16, 2024: Cellular Physiology and Biochemistry
keyword
keyword
22765
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.